These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20808246)

  • 1. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD.
    Fitzpatrick E; Mitry RR; Quaglia A; Hussain MJ; DeBruyne R; Dhawan A
    J Pediatr Gastroenterol Nutr; 2010 Oct; 51(4):500-6. PubMed ID: 20808246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
    Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
    Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.
    Lebensztejn DM; Wierzbicka A; Socha P; Pronicki M; Skiba E; Werpachowska I; Kaczmarski M
    Acta Biochim Pol; 2011; 58(4):563-6. PubMed ID: 22140659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
    Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C
    Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.
    Savvidou S; Hytiroglou P; Orfanou-Koumerkeridou H; Panderis A; Frantzoulis P; Goulis J
    J Clin Gastroenterol; 2009 Sep; 43(8):765-72. PubMed ID: 19525862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity.
    Emanuele E
    Hepatology; 2008 Dec; 48(6):2086-7; author reply 2087. PubMed ID: 19030167
    [No Abstract]   [Full Text] [Related]  

  • 8. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
    Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population.
    Zelber-Sagi S; Ratziu V; Zvibel I; Goldiner I; Blendis L; Morali G; Halpern Z; Oren R
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):262-9. PubMed ID: 22246329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Suzuki A; Angulo P; Lymp J; Li D; Satomura S; Lindor K
    Liver Int; 2005 Aug; 25(4):779-86. PubMed ID: 15998429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.
    Joka D; Wahl K; Moeller S; Schlue J; Vaske B; Bahr MJ; Manns MP; Schulze-Osthoff K; Bantel H
    Hepatology; 2012 Feb; 55(2):455-64. PubMed ID: 21993925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis.
    Talwalkar JA
    Hepatology; 2009 Oct; 50(4):1000-3. PubMed ID: 19787817
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
    Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
    J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between the severity of liver damage and the serum leptin level for nonalcoholic fatty liver disease].
    Kim KO; Park SH; Park CH; Han TH; Yoo KS; Kim JH; Lee MS; Kim DJ; Park CK; Cho HD
    Korean J Hepatol; 2005 Mar; 11(1):51-8. PubMed ID: 15788885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.
    Nobili V; Alkhouri N; Alisi A; Ottino S; Lopez R; Manco M; Feldstein AE
    Clin Gastroenterol Hepatol; 2009 May; 7(5):575-9. PubMed ID: 19268270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers.
    Mitry RR; De Bruyne R; Quaglia A; Hughes RD; Dhawan A
    Hepatology; 2007 Dec; 46(6):2047-8; author reply 2048. PubMed ID: 18046726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.